FLGT
Fulgent Genetics, Inc. · NASDAQ
- Sector Health Services
- Industry Medical/Nursing Services
- Website fulgentgenetics.com
- Employees(FY) 1012
- ISIN US3596641098
Performance
+1.47%
1W
+6.71%
1M
-12.95%
3M
-20.07%
6M
-23.52%
YTD
-38.05%
1Y
Profile
Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and next generation sequencer services related to hereditary cancer, cardiovascular genetics, reproductive health, and neurodegenerative genetics, as well as pharmacogenetic tests. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to enhance the therapeutic window and pharmacokinetic profile, or PK profile, of new and existing cancer drugs. The company also operates picture genetics platform which includes proprietary gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Investment Analysis Report: FLGT
Overview
FLGT is a company operating in the Health Services sector, specifically in the Medical/Nursing Services industry. The company has shown growth in its financial metrics over the past three years, with an increase in total assets, revenue, and net income. In this report, we will analyze FLGT's financial he...
Technical Analysis of FLGT 2024-05-10
Overview:
In analyzing the technical indicators for FLGT over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive assessment of the stock's potential price movement. By examining these key aspects, we aim to offer valuable insights and predictions for the next few days.
Trend Anal...
Recent News & Updates
- 2024-05-15 04:21
Moffitt and Fulgent Pharma partner on personalised cancer therapies(Pharmaceutical Technology)
- 2024-05-14 16:05
- 2024-05-14 04:05
- 2024-05-13 21:00
- 2024-05-06 15:32
- 2024-05-04 03:04
- 2024-05-03 22:46
Q1 2024 Fulgent Genetics Inc Earnings Call(Thomson Reuters StreetEvents)
- 2024-05-03 21:15
- 2024-05-03 21:15
- 2024-05-03 08:34
- 2024-05-03 08:15
- 2024-05-03 07:00
Fulgent Reports First Quarter 2024 Financial Results(Business Wire)
- 2024-05-02 23:53
- 2024-05-02 20:15
- 2024-05-02 19:00
Fulgent Reports First Quarter 2024 Financial Results(Businesswire)
- 2024-05-02 19:00
Fulgent Reports First Quarter 2024 Financial Results(Businesswire)
- 2024-04-23 20:00
FLGT: What does Argus have to say about FLGT?(Argus Research)
- 2024-04-11 16:05
- 2024-04-11 08:44
- 2024-04-11 04:05
- 2024-03-01 06:19
- 2024-03-01 05:48
- 2024-02-29 09:31
- 2024-02-28 22:18
Q4 2023 Fulgent Genetics Inc Earnings Call(Thomson Reuters StreetEvents)
- 2024-02-28 20:31
- 2024-02-28 07:35
- 2024-02-28 07:00
- 2024-02-27 18:00
- 2024-02-13 08:00
- 2024-02-12 19:00
Page 1 of 5
previousnext